DGX : Summary for Quest Diagnostics Incorporated - Yahoo Finance

U.S. Markets open in 1 hr 13 mins

Quest Diagnostics Incorporated (DGX)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
91.07+0.07 (+0.08%)
At close: 4:02PM EST
People also watch
LHBCRCAHDVAABC
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close91.00
Open91.05
Bid0.00 x
Ask0.00 x
Day's Range90.50 - 91.21
52 Week Range59.66 - 93.84
Volume1,207,771
Avg. Volume1,128,940
Market Cap12.63B
Beta0.91
PE Ratio (TTM)19.33
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.80 (1.98%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Quest Diagnostics (DGX) Launches HBV Quantitative Test
    Zacks4 days ago

    Quest Diagnostics (DGX) Launches HBV Quantitative Test

    Quest Diagnostics Inc. (DGX), a global provider of diagnostic information services, recently rolled out Hepatitis B Virus (HBV) Quantitative Test.

  • Quest Diagnostics CEO reveals the best and worst things about Obamacare
    Yahoo Finance6 days ago

    Quest Diagnostics CEO reveals the best and worst things about Obamacare

    Few businesses have as big of a reach in American health care as Quest Diagnostics (DGX). Despite any proposed change to the Affordable Care Act (ACA)—otherwise known as Obamacare—Quest expects to continue its key position in the health care industry, according to CEO Steve Rusckowski. “We’re 2% of health care costs and we determine about 70% of the decisions that are made with health care,” Rusckowski said.

  • PR Newswire6 days ago

    Quest Diagnostics Launches Nation's First Hepatitis B Virus Quantitative Test to Help Assess Response to Antiviral Therapy

    MADISON, N.J., Jan. 18, 2017 /PRNewswire/ -- Quest Diagnostics (DGX), the world's leading provider of diagnostic information services, today announced the launch of a new test service that helps physicians evaluate a patient's response to drug therapies used to treat infection with the hepatitis B virus (HBV). The first test of its kind available in the United States, the test is significant because it may help physicians tailor more effective treatments for the up to 2.2 million individuals infected with HBV. With this insight, physicians are better positioned to monitor response to antiviral medications, and may enable them to modify or adjust treatment to help minimize the likelihood of progression and reactivation.